Strategic Management in Global Context: Pharmaceutical Industry

Strategic Management in a Global Context
SOE09401: Coursework assignment
Case Study Analysis
Case 1: The global pharmaceutical industry: world saviour or loathed pariah? [pages 549 - 560 of the 13th Edition]
Case 2: Mars' and Nestlé's diversification into veterinary clinics [PAGES 644]. [pages 644 – 651 of the 13th Edition]
This case studies can be found in the case study section of the 13th Edition of the prescribed reading. You can access this using the link on Moodle in the Resources section.
Whittington et al (2020) Exploring Strategy: Text and Cases 13th edition

This assessment contributes 90% of your final mark for this module and you are required to analyse two case studies on the global pharmaceutical industry and Mars' and Nestlé's. When answering the case questions below only use information the global pharmaceutical industry and Mars' and Nestlé's.contained in the case study. Your marks will be penalised if you use information on the company from alternative sources as it is your assessment of the case information provide which is being assessed.
You are to answer the questions in a report format. Hence, your report should consist of executive summary, table of content, headings, subheadings, tables and figures, and reference list. Avoid bullet points.
Questions
1. Drawing on your knowledge of the PESTEL model, analyse the external environment facing global pharmaceutical industry and identify the key external factors which impact on the company. (15%)
2. Using Porter’s Five Forces framework, analyse the attractiveness of the global pharmaceutical industry. Support your analysis with evidence from the global pharmaceutical industry case study (25%)
3. Using Porter’s Generic Strategies, analyse the competitive strategy employed by Mars and Nestlé. Support your analysis with evidence from the case study. (25%)
4. Using the Ansoff’s matrix, analyse the direction of growth that Mars and Nestlé has undertaken to grow their business. Provide recommendations for the firm's future growth. (25%) Mark allocated for the presentation of analysis, use of case evidence and conclusions. (10%